An Open Letter to Advisory Bodies\(^1\) Regarding
Low-Dose Total Body Irradiation for Systemic Treatment of Cancer

May 30, 2014

Dear Colleagues,

Though adjuvant chemotherapy has been a standard of practice in the systemic treatment of many cancers, its adverse side effects are of considerable concern. The possible side effects include anemia, fatigue, gastro-intestinal dysfunction, hair loss, infection, memory changes, etc. (1). These side effects diminish drastically the quality of life including long-term reduced physical functioning and overall general health (2). In addition, chemotherapy is associated with a life-long reduced rate of employment (3). Hence it is very important to seek alternative approaches for systemic therapy which have less harmful side effects.

One adjuvant treatment that has similar or better outcomes with no symptomatic adverse side effects is low-dose fractionated total body irradiation (LDTBI). In the 1970s, LDTBI at the rate of 15 cGy per fraction, and 10 fractions applied over 5 weeks, had been studied in clinical trials of lymphosarcoma (4) and non-Hodgkin’s lymphoma patients (5). The 4-year survival rates with adjuvant LDTBI were equivalent (4) or better (6) when compared to adjuvant chemotherapy, as seen in Figures 1 and 2 below. The main short-term side effects from LDTBI were hematological, with no observed long-term adverse side effects (5).

![Image of survival curve](https://example.com/survival_curve.png)

*Figure 1. Comparison between TBI and matched COP-treated group. Numbers of patients at risk for each time interval are shown. Differences between groups are not statistically significant.*

---

\(^1\) ICRP, NCRP, UNSCEAR, IAEA, WHO, NAS, ...
One of the reported concerns regarding total-body irradiation (TBI) is the increased risk of leukemias when high-dose TBI was followed with chemotherapy. However, all the observed increased leukemias in this study were in patients who had high cumulative TBI doses of 2 Gy or more and/or high radiation doses to the bone marrow. LDTBI using a cumulative dose of 1.5 Gy has been studied clinically. The hematological side effects were temporary, minimal, and well-tolerated and the efficacy of the systemic treatment was significantly advantageous. Successful results in further clinical trials should lead to its widespread acceptance as a standard effective systemic treatment of cancers without the severe side effects of the current standard-of-care chemotherapies.

A major obstacle in initiating any clinical trial of LDTBI is the current use of the linear no-threshold (LNT) model for radiation risk assessment by regulatory agencies, based on recommendations of international and national advisory bodies. Because of the LNT model-based concerns, researchers may be reluctant to propose clinical trials of LDTBI. Thus, it is not surprising that LDTBI has been under-investigated and under-utilized in spite of its potential. However, a considerable amount of evidence has accumulated clearly demonstrating that the LNT model is inconsistent with data (please see the compilation of evidence below).

In consideration of the above evidence, and in order to facilitate the study of this less deleterious systemic treatment of cancer, we ask you to make a declaration that you encourage the study of LDTBI for systemic cancer treatment, and that the LNT model, which is a conservative approach for calculating potential radiation risks, not be used to discourage the study of LDTBI.

We would be happy to discuss this matter with you or provide additional information for your consideration. Thank you for your kind attention to this important issue.

Sincerely,
Mohan Doss, Fox Chase Cancer Center, USA (mohan.doss@fccc.edu)
Allen Brodsky, Georgetown University, USA
Lu Cai, The University of Louisville, USA
Jerry Cuttler, Cuttler & Associates, Canada
Ludwik Dobrzynski, National Centre for Nuclear Research, Poland
Vincent J Esposito, University of Pittsburgh, USA
Ludwig E. Feinendegen, Heinrich-Heine University, Germany
Alan Fellman, Dade Moeller & Associates, Inc., USA
Krzysztof W. Fornalski, Polish Nuclear Society, Poland
Leo S. Gomez, Leo S. Gomez Consulting, USA
Marek K. Janiak, Military Institute of Hygiene and Epidemiology, Poland.
Brenda Laster, Ben Gurion University, Israel
Patricia Lewis, Free Enterprise Radon Health Mine, USA
Jeffrey Mahn, Sandia National Laboratories (Retired), USA
Mark L. Miller, Sandia National Laboratories, USA
Charles W. Pennington, Executive Nuclear Energy Consultant, USA
Jeffrey S. Philbin, Sandia National Laboratories (Retired), USA
Chary Rangacharyulu, University of Saskatchewan, Canada
Kanokporn Noy Rithidech, Stony Brook University, USA
Bobby R. Scott, Lovelace Respiratory Research Institute, USA (Retired)
Yehoshua Socol, Falcon Analytics, Israel
James S. Welsh, President-elect, American College of Radiation Oncology, USA
Ruth F. Weiner, Former Member of the NRC Advisory Committee on Nuclear Waste and Materials, USA

Note: All signers of this letter are members or associate members of SARI (Scientists for Accurate Radiation Information, http://radiationeffects.org/). The above letter represents the professional opinions of the signers, and does not necessarily represent the views of their affiliated institutions.

References:

Evidence for Threshold Dose-Response or for Radiation Hormesis in Human Studies

1. Threshold dose of ~10 Gy accumulated over many years in radium dial painters. Analysis of data from Rowland, 1983 in Sanders, 2010 on page 44.

2. Reduced cancer mortality from 12 cGy and 50 cGy radiation dose in villages near Mayak nuclear weapons facility. Kostyuchenko, 1994, Table 4.


4. Improved survival in non-Hodgkin’s lymphoma patients having interspersed 10 or 15 cGy total-body or half-body irradiation (TBI or HBI) for five weeks (total dose 1.5 Gy) between standard radiation treatments to tumor. Sakamoto, 2004.

5. Reduced overall cancers in Taiwan apartment residents having ~5 cGy radiation dose from Co-60 contaminated building materials. Data from Hwang, 2006, Table III.

Note: In spite of the reported increase of malignancies for a few subsets of data with poor statistics in Hwang, 2006, the overall cancer incidence declines at 5 cGy, as seen in the figure above and in Table III of the publication.
6. Reduced second cancers in radiation therapy patients in regions of body subjected to total dose of ~20 cGy, and threshold dose of >100 cGy for increased second cancers. Tubiana, 2011.


8. Threshold dose of greater than ~50 cSv for increased leukemias in Hiroshima atomic bomb survivors. Analysis of data from UNSCEAR 1958 in Cutler 2014.